TAVR market seen reaching $11.3 billion by 2033

By AI, Created 9:59 AM UTC, May 20, 2026, /AGP/ – Persistence Market Research says the global transcatheter aortic valve replacement market will grow from $7.1 billion in 2026 to $11.3 billion by 2033, driven by aging populations, wider patient eligibility and more minimally invasive procedures. North America leads now, while Asia Pacific is expected to grow fastest as hospitals expand access and infrastructure.

Why it matters: - The TAVR market is expanding as more patients and hospitals shift toward minimally invasive treatment for aortic stenosis. - The forecast points to stronger demand for structural heart procedures, better imaging and next-generation valve systems. - Broader use in younger and lower-risk patients could meaningfully increase the number of eligible procedures worldwide.

What happened: - Persistence Market Research projected the global transcatheter aortic valve replacement market at US$ 7.1 billion in 2026. - The firm forecast the market will reach US$ 11.3 billion by 2033, implying a 6.9% CAGR from 2026 to 2033. - The report was issued from London on May 7, 2026. - The report identified aging populations, rising aortic stenosis prevalence, expanding indications and greater patient awareness as core growth drivers.

The details: - North America is expected to hold about 45% of the market in 2026, supported by high healthcare spending and advanced cardiovascular infrastructure. - Asia Pacific is projected to post the fastest growth through 2033 because of rising disease burden and expanding healthcare delivery. - Transfemoral access remains the most widely used procedure approach because it is minimally invasive and supports faster recovery. - Transapical access is the fastest-growing procedure segment and is used for patients with complex anatomy. - Hospitals remain the largest end-user segment because they have specialized teams and advanced infrastructure. - Ambulatory surgical centers are the fastest-growing end-user segment because of lower costs, convenience and regulatory support. - The market is segmented by procedure, end-user, material and region, including nitinol, cobalt-chromium, stainless steel and polymer composites. - Regional coverage in the report includes North America, Europe, East Asia, South Asia & Oceania, Latin America, and the Middle East & Africa. - The competitive landscape is moderately consolidated, with Edwards Lifesciences, Medtronic plc, Boston Scientific, Abbott Laboratories and MicroPort Scientific among the leading companies. - The report listed additional companies including Meril Life Sciences, Peijia Medical, JenaValve Technology, Venus Medtech, Suzhou Jiecheng Medical, Braile Biomédica, Anteris Technologies, Tendyne Holdings and HighLife Medical. - The report highlighted a May 2025 FDA approval of Edwards Lifesciences’ SAPIEN 3 platform for asymptomatic severe aortic stenosis patients. - The report also noted March 2025 five-year durability data for Medtronic’s Evolut system in low-risk patients. - The report included links for a free sample, custom insights and the complete market report.

Between the lines: - The report suggests TAVR is moving from a niche therapy for high-risk patients toward a broader structural heart platform. - Reimbursement gaps and high procedure costs still limit adoption, especially in emerging markets. - Long-term durability concerns, pacemaker risk and paravalvular leak remain key hurdles for younger patients with longer life expectancy. - Valve-in-valve TAVR is gaining traction as more patients with older surgical bioprosthetic valves need reintervention. - Hospitals are building integrated heart teams and referral networks, which can speed diagnosis and treatment decisions.

What’s next: - More regulatory expansion and guideline updates could open TAVR to additional patient groups. - Ongoing improvements in valve design, delivery systems and imaging are likely to support procedural efficiency and outcomes. - North America should remain the largest market, while Asia Pacific is positioned to capture the fastest incremental growth. - Structural heart programs are likely to keep broadening into mitral and tricuspid interventions, strengthening the ecosystem around TAVR.

The bottom line: - TAVR is set for steady global growth as clinical adoption widens and technology improves, but pricing, reimbursement and durability issues will shape how fast the market can scale.